🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

An International Health Concern

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million instances annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Outcomes and Global Access

Based on findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This places it at an equal footing with the current standard treatment, which uses a dual-drug approach. The study involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Clinicians directly involved have shared optimism. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.